A. Awada

M. Piccart, I. Vergote, P. Willemse, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

J. Bourhis, C. Borel, Y. Humblet, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

G. Bodoky, J. Douillard, A. Awada, 2020, ESMO Open.

97 Phase I study of cetuximab (C225)in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN)

C. Borel, A. Awada, F. Rivera, 2003 .

Learning from the "tsunami" of immune checkpoint inhibitors in 2015.

A. Awada, H. Kourie, G. Awada, 2016, Critical reviews in oncology/hematology.

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion

D. V. Von Hoff, L. Smith, H. Burris, 1994, Anti-cancer drugs.

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.

J. Machiels, E. Van Cutsem, P. Pauwels, 2021, Critical reviews in oncology/hematology.

Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: A promising anti-tumor agent

M. Piccart-Gebhart, A. Awada, S. Bartholomeus, 2002 .

Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.

P. Flamen, A. Awada, T. Gil, 2006, Anti-cancer drugs.

Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors

M. Piccart, A. Awada, T. Gil, 2009, Investigational New Drugs.

Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies

E. Raymond, D. V. Von Hoff, H. Burris, 1998, Investigational New Drugs.

Potential involvement of the IL-33–ST2 axis in the pathogenesis of primary Sjögren's syndrome

A. Awada, J. Rasschaert, V. Gangji, 2014, Annals of the rheumatic diseases.

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

M. Piccart, J. Bonneterre, A. Awada, 2014 .

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.

M. Piccart, J. Sculier, A. Awada, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

N. Agarwal, J. Machiels, K. Wisinski, 2016, The oncologist.

Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.

J. Castelijns, J. Kaanders, A. Awada, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.

E. Raymond, A. Italiano, S. Faivre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.

E. Raymond, A. Italiano, S. Faivre, 2010 .

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

D. Strumberg, S. Seeber, D. Voliotis, 2006, European journal of cancer.

Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)

D. Schadendorf, U. Martens, S. Topalian, 2017 .

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

Suzanne F. Jones, M. Piccart, H. Burris, 2009, Cancer Chemotherapy and Pharmacology.

TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.

É. Remenár, A. Awada, J. Buter, 2016 .

University of Groningen A Kinome RNAi Screen in Drosophila Identifies Novel Genes Interacting with Lgl, aPKC, and Crb Cell Polarity Genes in Epithelial Tissues

G. Koutsodontis, É. Remenár, A. Psyrri, 2017 .

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer

J. Tabernero, A. Awada, V. Moreno, 2022, ESMO open.

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

G. Shapiro, I. Braña, A. Awada, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, ESMO Open.

Impact of tumor sequencing on the use of anticancer drugs

C. Desmedt, A. Awada, P. Aftimos, 2014, Current opinion in oncology.

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma

G. Ghanem, A. Awada, F. Journé, 2020, Cancers.

Is VEGF a predictive biomarker to anti-angiogenic therapy?

A. Awada, A. Shamseddine, Z. Otrock, 2011, Critical reviews in oncology/hematology.

Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature

R. Mahfouz, A. Awada, H. Bahmad, 2017, Front. Med..

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics

S. Loi, C. Criscitiello, C. Twelves, 2021, Expert opinion on biological therapy.

Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.

A. Awada, C. Lonez, D. Gilham, 2021 .

The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.

C. Solinas, A. Awada, M. Scartozzi, 2017, Cancer treatment reviews.

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

A. Awada, S. Bartholomeus, T. Gil, 2012, European journal of cancer.

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer

G. Curigliano, P. LoRusso, K. Kern, 2016, Oncotarget.

Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice.

A. Awada, Y. Lalami, Ahmad Awada, 2016, Cancer treatment reviews.

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

A. Awada, H. Kourie, M. Chaix, 2016, Expert opinion on drug metabolism & toxicology.

Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients

A. Awada, T. Gil, F. Aoun, 2016, Journal of Endocrinological Investigation.

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

T. Gorlia, J. Bernier, É. Remenár, 2007, The New England journal of medicine.

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

M. Piccart, M. Uttenreuther-Fischer, A. Awada, 2012, Investigational New Drugs.

Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges

A. Awada, A. Shamseddine, Z. Otrock, 2013, Current opinion in oncology.

Phase IB Dose-Escalation Study of BEZ235 or BKM120 in Combination with Paclitaxel (PTX) in Patients With Advanced Solid Tumors

J. Machiels, L. Dirix, L. Paz-Ares, 2012 .

Novel mechanisms and approaches in the medical therapy of solid cancers.

A. Awada, H. Kourie, G. Awada, 2015, Discovery medicine.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

G. Salles, J. Machiels, D. Cunningham, 2019, Molecular Cancer Therapeutics.

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

S. Peters, A. Santoro, K. Zaman, 2020, The Lancet. Oncology.

Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials

A. Awada, F. Thomas, 2015 .

The pipeline of new anticancer agents for breast cancer treatment in 2003.

M. Piccart, F. Cardoso, A. Awada, 2003, Critical reviews in oncology/hematology.

Phase I clinical and pharmacology study of the novel epothilone analog BMS-247550 given weekly in patients advanced solid tumors

M. Piccart-Gebhart, H. Burris, A. Awada, 2001 .

Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials

C. Takimoto, A. Awada, 2008, Cancer Chemotherapy and Pharmacology.

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

M. Piccart, D. Strumberg, B. Schwartz, 2005, British Journal of Cancer.

Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.

A. Awada, A. Shamseddine, Z. Otrock, 2009, Critical reviews in oncology/hematology.

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

T. Berghmans, A. Awada, M. Remmelink, 2012, Lung Cancer.

Targeted therapies of solid cancers: new options, new challenges

A. Awada, P. Aftimos, 2013, Current opinion in oncology.

Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients

A. Awada, E. de Azambuja, G. Awada, 2017, Expert opinion on drug metabolism & toxicology.

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

A. Awada, T. Guren, N. Steeghs, 2021, British Journal of Cancer.

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

J. Schellens, H. Verheul, A. Awada, 2020, British Journal of Cancer.

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

S. Peters, A. Santoro, K. Zaman, 2020, Lung cancer.

Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.

R. Mahfouz, A. Awada, A. Shamseddine, 2012, Critical reviews in oncology/hematology.

Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.

V. D’Hondt, A. Awada, L. dal Lago, 2008, The oncologist.

Novel treatment strategies for malignant melanoma: a new beginning?

V. D’Hondt, A. Awada, B. Kasper, 2007, Critical reviews in oncology/hematology.

Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies

A. Awada, P. Barthélémy, T. Gil, 2019, AntiCancer Research.

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

C. Twelves, A. Awada, V. Diéras, 2018, Cancer treatment reviews.

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

M. Piccart, J. Baselga, F. Cardoso, 2008, British Journal of Cancer.

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

S. Peters, J. Soria, A. Stathis, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

A. Awada, E. de Azambuja, M. Franzoi, 2021, Breast.

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

J. Bogaerts, L. Hayward, P. Fumoleau, 2014, Breast.

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

M. Piccart, A. V. van Oosterom, A. Awada, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.

D. Larsimont, M. Piccart-Gebhart, A. Awada, 2018, Bulletin du cancer.

Extra-osseous Ewing sarcoma of the thyroid gland mimicking a hemorrhagic cyst of Hashimoto thyroiditis

A. Awada, T. Gil, C. Jungels, 2017 .

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

Bing-he Xu, L. Dirix, A. Awada, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

L. Chow, A. Awada, I. Božović-Spasojević, 2012, Cancer treatment reviews.

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

T. Berghmans, A. Awada, S. Bartholomeus, 2015, Investigational New Drugs.

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

A. Awada, S. Bartholomeus, T. Gil, 2008 .

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

J. Machiels, A. Awada, J. Brayer, 2023, The Lancet. Haematology.

Will the dark sky over advanced renal cell carcinoma soon become brighter?

M. Piccart, V. D’Hondt, A. Awada, 2005, European journal of cancer.

Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.

F. Caponigro, X. Pivot, A. Awada, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.

C. Rolfo, A. Awada, M. Peeters, 2014 .

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer

D. Larsimont, V. Detours, C. Solinas, 2017, Front. Immunol..

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

M. Piccart, A. Awada, S. Giacchetti, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours

J. Spicer, A. Awada, P. Barthélémy, 2015 .

M. Piccart, J. Bonneterre, A. Awada, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.

G. Curigliano, J. Spicer, A. Awada, 2018 .

Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients

W. Jusko, P. Zhao, H. Gelderblom, 2009, Cancer Chemotherapy and Pharmacology.

New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.

M. Piccart-Gebhart, A. Awada, P. Harnett, 2008, Critical reviews in oncology/hematology.

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

M. Piccart, M. Maetens, P. Flamen, 2015, BMC Cancer.

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

M. Piccart, M. Maetens, P. Flamen, 2013, BMC Cancer.

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

M. Piccart, J. Wanders, J. Verweij, 2002, European journal of cancer.

Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients

W. Jusko, P. Zhao, H. Gelderblom, 2009, Cancer Chemotherapy and Pharmacology.

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

J. Soria, C. Rolfo, A. Awada, 2017, Clinical Cancer Research.

Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis.

A. Awada, M. Soyfoo, C. Nicaise, 2021, Clinical and experimental rheumatology.

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

M. Piccart, A. Awada, G. Deliens, 2016, Journal of geriatric oncology.

Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer

A. Awada, A. Gombos, P. Aftimos, 2016, Expert opinion on emerging drugs.

Management of HER-2/neu-positive metastatic breast cancer

M. Piccart-Gebhart, A. Awada, 2008 .

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

A. Ravaud, S. Salas, C. Borel, 2020, Journal for ImmunoTherapy of Cancer.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

E. Perez, Y. Chia, J. Hamm, 2013, The Lancet. Oncology.

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

J. Bergh, F. Cardoso, K. Kern, 2012, Breast.

Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors.

T. Berghmans, A. Awada, T. Taube, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.

M. Piccart, J. Wanders, A. Awada, 2003, European journal of cancer.

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

J. Galon, J. Spicer, F. Hermitte, 2021, Clinical Cancer Research.

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?

A. Awada, P. Aftimos, 2011, Advances in therapy.

Oncological care organisation during COVID-19 outbreak

J. Machiels, H. Rugo, H. Wildiers, 2020, ESMO Open.

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

F. Hodi, Y. Bang, M. Sznol, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Is tailored adjuvant treatment for colon cancer possible?

A. Awada, M. Eynde, A. Hendlisz, 2010, Clinical colorectal cancer.

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

M. Piccart-Gebhart, L. Ameye, A. Awada, 2020, Clinical colorectal cancer.

Thrombo-Embolic Events in Cancer Patients with Impaired Renal Function

J. Canon, A. Awada, J. Baurain, 2014 .

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

W. Oyen, O. Hoekstra, E. D. de Vries, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma

A. Jager, J. Schellens, H. Verheul, 2014 .

New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective

M. Piccart, A. Awada, A. Hendlisz, 2004, Expert review of anticancer therapy.

Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

Anticancer drug development: moving away from the old habits.

D. Zardavas, A. Awada, F. Ades, 2014, Current opinion in oncology.

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

J. Bourhis, C. Borel, A. Schueler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors

J. Soria, A. Awada, S. Aspeslagh, 2016, Anti-cancer drugs.

Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors

M. Piccart-Gebhart, A. Awada, H. Bleiberg, 2001 .

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

J. Schellens, E. Voest, A. Awada, 2013, Investigational New Drugs.

Controversies in adjuvant systemic therapy of breast cancer. Part I: areas of controversy in the adjuvant systemic therapy of endocrine non-responsive breast cancer

R. Gelber, F. Cardoso, M. Piccart-Gebhart, 2002 .

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

S. Aamdal, A. Awada, B. Venugopal, 2015, Cancer Chemotherapy and Pharmacology.

PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).

W. Oyen, O. Hoekstra, P. Flamen, 2014 .

A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies

F. Cardoso, S. Ramalingam, E. Heath, 2011, Investigational New Drugs.

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

M. Piccart, K. Willard-Gallo, L. Ameye, 2022, Journal of Cancer Research and Clinical Oncology.

NT-23PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

A. Jager, J. Schellens, C. Anders, 2014 .

Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

K. Zaman, L. Paz-Ares, A. Awada, 2019, Journal of Clinical Oncology.

Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).

E. Winer, R. Berger, R. Kurzrock, 2012 .

Rare Features of Dermatomyositis in a Patient with Ovarian Cancer.

A. Awada, L. dal Lago, T. Pepersack, 2020, European journal of case reports in internal medicine.

Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC).

G. Curigliano, P. LoRusso, K. Kern, 2015 .

A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors

M. Piccart-Gebhart, A. Meert, A. Awada, 2001 .

Pharmacokinetics of Tipifarnib After Oral and Intravenous Administration in Subjects With Advanced Cancer

M. Piccart-Gebhart, L. Dirix, Peter M. Porre, 2006, Journal of clinical pharmacology.

Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).

E. Smit, S. Novello, T. Gauler, 2013 .

Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.

A. Awada, T. Gil, P. Schöffski, 2012 .

Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.

A. Awada, S. Bartholomeus, T. Gil, 2010 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study

M. Piccart, P. Flamen, M. Paesmans, 2014, BMC Cancer.

Phase I–II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5-FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)

J. Castelijns, A. Awada, J. Vermorken, 1999 .

LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.

J. Spicer, A. Awada, J. Baurain, 2017 .

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.

P. Pauwels, C. Rolfo, A. Awada, 2016 .

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

M. Piccart, M. Nooij, L. Beex, 2002, European journal of cancer.

Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours.

J. Machiels, A. Awada, P. Schöffski, 2023, European journal of cancer.

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

S. Aamdal, J. Wanders, J. Verweij, 2000, Cancer Chemotherapy and Pharmacology.

A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors.

M. Piccart, M. Uttenreuther-Fischer, A. Awada, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors.

J. Machiels, D. Cunningham, A. Awada, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers

M. Piccart, A. Awada, T. Gil, 2004, Anti-cancer drugs.

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

K. Zaman, J. Sehouli, A. Leary, 2023, Investigational new drugs.

P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose

A. Santoro, K. Zaman, L. Paz-Ares, 2019, Journal of Thoracic Oncology.

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

K. Odunsi, A. Awada, J. Brayer, 2019, Blood.

Final results from an open-label, randomised, phase II study of adecatumumab (MT201), a fully human anti-EpCAM antibody, in patients with metastatic breast cancer

L. Dirix, M. Schuler, M. Scheulen, 2007 .

Pharmacokinetics (PK) of free and total paclitaxel after equal doses of paclitaxel injectable emulsion and paclitaxel injection

H. Gelderblom, A. Awada, J. Vermorken, 2005 .

Current-day precision oncology: from cancer prevention, screening, drug development, and treatment – have we fallen short of the promise?

A. Awada, G. Morgan, P. Aftimos, 2016, Current opinion in oncology.

The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.

A. Awada, H. Kourie, G. Awada, 2017, Immunotherapy.

Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.

R. Mahfouz, A. Awada, A. Shamseddine, 2012, Critical reviews in oncology/hematology.

Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer

A. Awada, A. Gombos, P. Aftimos, 2016, Expert opinion on emerging drugs.

Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges

A. Awada, A. Shamseddine, Z. Otrock, 2013, Current opinion in oncology.

Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors.

G. Rabinovich, E. Raymond, P. Hérait, 2013 .

Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.

A. Leary, A. Awada, B. Besse, 2018 .

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Jeffrey W. Clark, H. Hirte, H. Lenz, 2007, The oncologist.

Trabectedin in sarcoma

A. Awada, T. Gil, 2008 .

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

C. Twelves, A. Awada, V. Diéras, 2018, Cancer treatment reviews.

397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)

K. Nackaerts, B. Hellerstedt, S. Gadgeel, 2010 .

Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors.

L. Chow, R. Epstein, A. Awada, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.

C. Twelves, A. Awada, M. Jové, 2016, Critical reviews in oncology/hematology.

Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.

A. Awada, A. Shamseddine, Z. Otrock, 2009, Critical reviews in oncology/hematology.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

N. Girard, J. V. Von Roenn, B. Coiffier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

INTRAVITREAL METHOTREXATE IN VEMURAFENIB-INDUCED UVEITIS

A. Awada, E. Motulsky, A. Dugauquier, 2023, Retinal cases & brief reports.